SUSTAIN trial programme: difference between revisions
Diff·revision 16 → 17·12:45, 9 Aug 2025
Difference between revision 16 and revision 17 of SUSTAIN trial programme. 3 lines changed; the page grew by 425 bytes.
| Revision 16 — 14:42, 28 Jun 2025 EndpointEnid (talk) convert a hard-coded date to the house format 4,728 bytes ±0 | Revision 17 — 12:45, 9 Aug 2025 TallySheetTad (talk) fix a broken wikilink 5,153 bytes +425 | ||
|---|---|---|---|
| 39 | This is the source of a persistent confusion when SUSTAIN 7 or the tirzepatide comparison in SURPASS-2 are cited as though they compared maximal doses. They did not, and the distinction changes what the comparison means. See [[Tirzepatide]].{{r|lincoff2023}} | 39 | This is the source of a persistent confusion when SUSTAIN 7 or the tirzepatide comparison in SURPASS-2 are cited as though they compared maximal doses. They did not, and the distinction changes what the comparison means. See [[Tirzepatide]].{{r|lincoff2023}} |
| 40 | 40 | ||
| + | 41 | Weight reduction in SUSTAIN is a secondary outcome in a glycaemic trial, and the populations differ in body-mass index at entry. Comparing a weight figure from a diabetes trial with one from an obesity trial compares two different quantities in two different populations.{{r|ich_e9}} | |
| + | 42 | ||
| 41 | == References == | 43 | == References == |
| 42 | {{reflist}} | 44 | {{reflist}} |
| ⋮ | ⋮ | ||
| 44 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). DOI:10.1056/NEJMoa1607141. PMID 27633186.</ref> | 46 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). DOI:10.1056/NEJMoa1607141. PMID 27633186.</ref> |
| 45 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 47 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| + | 48 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | |
| 46 | 49 | ||
| 47 | == See also == | 50 | == See also == |